Why Novavax Shares Are Trading Lower Today

Novavax NVAX shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authorization for its COVID-19 vaccine until June.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.

At the time of publication, shares of Novavax were trading 8.14% lower at $161.67. The stock has a 52-week low of $19.62 and a 52-week high of $331.68